News About: Pharm. Industry
Hanmi Pharm appoints Jong-Soo Woo & Sae-Chang Kwon as new president
In order to re-gain trust from the market and innovate poorness in the general business management, like delayed notice, inadequacy in management of closed information and revocation of some license agreement, Hanmi P...
Daewoong’s vision to make India Research Center a hub for global approvalDaewoong Pharmaceutical(CEO Jong-Wook Lee) announced it had a discussion for 4 days from the 26th of February for the management and local researchers under a vision to make the...
|
Hanmi Pharm Group originally blocks use of closed information from employeesIn order to fundamentally block possibility to use closed information from its employees, Hanmi Pharm Group made strict regulations, decided them at the board meeting and enforc...
|
Listed pharmas pay KRW 200 billion cash dividends this year
The amount of cash dividends declared by listed pharmaceutical company was decreased from the last year’s KRW 250 billion to KRW 200 billion.
Even though it is only 80% of the last year’s amount, considering Hanmi Ph...
2 of 3 listed pharmas are having under 10% operating profit ratio
While increases in introduced products and SG&A expenses have been criticized as the main causes to weaken the pharmaceutical companies’ profitability, it was observed there were only 21 pharmaceutical companies excee...
Which pharmas have high chance to fight against big pharmas in global market?
Pharmaceutical companies have drawn a big picture for the competition against global pharmaceutical companies in the leading markets, but the competition has not started yet.
The place where the pharmaceutical compan...
‘Expense Report for Economic Benefits’ confirmed to include signatures, but exclude license number
A form for the ‘Expense Report for Economic Benefits,’ which will play a key role in exposing illegal rebates, was practically confirmed. The medical and pharmaceutical fields agreed over excluding license numbers of ...
Pharmas will shoot global new drugs within 2-3 years with devotion to pipelines
As Korean pharmaceutical companies’ pipelines led to new drugs, it seems the era that they compete against multinational pharmaceutical companies will raise. Korean pharmaceutical companies’ CEOs have raised an expect...
Listed pharmaceutical companies weakened in profitability while recording similar amount of sales with the average year
Although listed pharmaceutical companies recorded a growth rate that is approximate to 7%, it was analyzed they were weakened in profitability.
According to the Yakup Shinmoon’s analysis result of 57 KOSPI and KOSDAQ...
MSD Korea appoints Jae-Yeon Choi as Head-Overseas Cooperation
MSD Korea announced appointment of Ms. Jae-Yeon Choi, a new executive director, as Head-Overseas Cooperation from the 8th of March.
After joining in the multinational pharmaceutical company Lilly Korea in 2004, Jae-Y...
